Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.51 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13702138 | 0.81 | MLYCD (0.65) | TRPV1TLR7HDAC3HDAC1HDAC2 | |
| SCHEMBL28779668 | 0.77 | HDAC3 (0.49) | TRPV1RAPGEF3TLR7HDAC3HDAC1 | |
| SCHEMBL2949064 | 0.76 | TRPV1 (0.52) | TRPV1TLR7HDAC3HDAC1HDAC2 | |
| SCHEMBL15129171 | 0.75 | TRPV1 (0.61) | TRPV1TLR7HDAC3HDAC1HDAC2 | |
| SCHEMBL14880391 | 0.75 | TRPV1 (0.61) | TRPV1TLR7HDAC3HDAC1HDAC2 | |
| SCHEMBL18896223 | 0.75 | ALDH1A1 (0.56) | TRPV1HDAC3HDAC1HDAC2EPHX2 | |
| SCHEMBL20074625 | 0.74 | RAPGEF3 (0.52) | TRPV1RAPGEF3HDAC3HDAC1HDAC2 | |
| SCHEMBL379229 | 0.74 | ALDH1A1 (0.49) | TRPV1RAPGEF3TLR7HDAC3HDAC1 | |
| SCHEMBL2650529 | 0.74 | TRPV1 (0.59) | TRPV1TLR7HDAC3HDAC1HDAC2 | |
| SCHEMBL2208745 | 0.74 | HPGD (0.63) | TRPV1TLR7HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227863-A1 | Organic Compounds | NOVARTIS AG | 2008-09-18 | — | — | US | disclosed |
| EP-1910278-A1 | AMIDONITRILE COMPOUNDS | Novartis AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007017088-A1 | AMIDONITRILE COMPOUNDS | NOVARTIS AG (CH) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227863-A1 | Organic Compounds | OXER1, AOX1, CYP1A1 | TRPV1 715/4885RAPGEF3 3048/4885TLR7 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.